The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...

In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...

Sales of the company's blockbuster weight-loss drugs Mounjaro and Zepbound grew to $3.53 billion and $1.91 billion, respectively, below expectations of $3.65 billion and $2.04 billion. Eli Lilly ...

The company said last month that it expected to report sales of diabetes drug Mounjaro and weight-loss treatment Zepbound below analysts' expectations for a second quarter in a row. The US ...

Lilly said on a call with analysts that it still believed there was huge demand for its weight-loss drug Zepbound and diabetes treatment Mounjaro from hundreds of millions of patients. The ...